Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in Advanced Ovarian Cancer with ABCB1 Fusion
NCT03933761Phase 2Withdrawn
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Jul 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pamiparib in ovarian cancer and carcinosarcoma, sponsored by Australia New Zealand Gynaecological Oncology Group. Primary endpoint: Clinical Benefit Rate at 16 weeks. Planned start Jul 2019; status: withdrawn.
02
Drugs
pamiparib
03
Conditions
ovarian cancercarcinosarcoma
Beyond the preview
Go deeper on NCT03933761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933761.